Empowering Health, to make a difference in your patients’ Quality of Life.
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESDE Structure</td>
<td>2</td>
</tr>
<tr>
<td>Committees</td>
<td>2</td>
</tr>
<tr>
<td>Welcome Message</td>
<td>3</td>
</tr>
<tr>
<td>Faculty</td>
<td>4</td>
</tr>
<tr>
<td><strong>Scientific Programme</strong></td>
<td></td>
</tr>
<tr>
<td>Pre-Course I</td>
<td>6</td>
</tr>
<tr>
<td>Pre-Course II</td>
<td>8</td>
</tr>
<tr>
<td>Congress</td>
<td>9</td>
</tr>
<tr>
<td>Posters</td>
<td>24</td>
</tr>
<tr>
<td>General Information</td>
<td>32</td>
</tr>
<tr>
<td>Scientific Meetings</td>
<td>35</td>
</tr>
<tr>
<td>Major Sponsors’ Profiles</td>
<td>36</td>
</tr>
<tr>
<td>Exhibition plan</td>
<td>40</td>
</tr>
<tr>
<td>Acknowledgments</td>
<td>43</td>
</tr>
</tbody>
</table>
Committees

ESDE Executive Board

Magnus Nilsson | President
Riccardo Rosati | General Secretary
Philippe Nafteux | Treasurer
Richard van Hillegersberg Councilor, Chairman of ESDE educational committee

President of the Congress

Theodore Liakakos

Local Organizing Committee

Alexandros Charalabopoulos
Dimitrios Schizas
George Karamanolis
Ioannis Papanikolaou

National Scientific Committee

Andreas Alexandrou
Konstantinos Ballas
Dionysios Dellaportas
Gerasimos Douridas
Michael Karamouzis
Ioannis Karavokyros
Aristotelis Kechagias
Anna Koumarianou
Dimitrios Lapatsanis
Orestis Lyros
Paris Pappas
Grigoris Paspatis
Dimitrios Roukos
Ioannis Rouvelas
Elias Sdralis
Dimitrios Theodorou
Costas Triantafillou
Valantis Vergadis
Antonios Vezakis
Dear Colleagues,

On behalf of the European Society for Diseases of the Esophagus, it is my honor and pleasure to welcome you to the ESDE 2019 Meeting which takes place in Athens, Greece, November 20-22, 2019.

The ESDE is the premier multi-disciplinary European organization, branch of the International Society for Diseases of the Esophagus (ISDE). Its annual meetings aim to gather together all specialties involved in the clinical management and research of esophageal diseases. The rapid developments in molecular biology, diagnosis, staging and treatments require continuous education.

The target of this ESDE Annual Meeting is to present all major progresses in esophageal diseases and our efforts are focusing to prepare a top level multidisciplinary program that we hope you will find interesting. Young investigators have submitted abstracts for oral or poster presentations.

Athens is a beautiful city with a rich cultural and architectural heritage mixed with modernity and it is easily accessible from all over the world.

We will do our best to offer you an unforgettable Meeting.

We welcome you in Athens, in 2019.

Theodore Liakakos
Congress President
Faculty

Alexandrou Andreas | Greece
Bonavina Luigi | Italy
Botha Abraham (Abrie) | United Kingdom
Charalabopoulos Alexandros | Greece
Chaudry Asif | United Kingdom
Cuesta Miguel | The Netherlands
De Manzoni Giovanni | Italy
Dellaportas Dionysios | Greece
Depypere Lieven | Belgium
Dimitriadis Stavros | Germany
Emmanouil Theodoros | Greece
Gazouli Maria | Greece
Georgopoulos Sotirios | Greece
Geroulanos Stefanos | Greece
Gockel Ines | Germany
Griffin Michael | United Kingdom
Griffiths Ewen | United Kingdom
Grimminger Peter | Germany
Hanna George | United Kingdom
Kalliakmanis Ioannis | Greece
Karamanolis Georgios | Greece
Karamouzis Michael | Greece
Karatzas Pantelis | Greece
Karavokyros Ioannis | Greece
Kechagias Aristotelis | Finland
Kofokotsios Alexandros | Greece
Lerut Toni | Belgium
Liakakos Theodore | Greece
Lindblad Mats | Sweden
Lorenzi Bruno | Italy
Low Donald | USA
Lundell Lars | Sweden
Lyros Orestis | Germany
Manolakis Anastasios | Greece
Markar Sheraz | United Kingdom
Mavrogenis Georgios | Greece
Michopoulos Spyridon | Greece
Moenig Stefan | Switzerland
Moorthy Krishna | United Kingdom
Nafteux Philippe | Belgium
Nilopoulos Antonios | Greece
Nilsson Magnus | Sweden
O’Hara David | United Kingdom
Oustamanolakis Pantelis | Greece
Panagiotakopoulos Dimitrios | Greece
Papanikolaou Ioannis | Greece
Faculty

Papastergiou Vasilios | Greece
Paraskeva Konstantina | Greece
Penagini Roberto | Italy
Pera Manuel | Spain
Piessen Guillaume | France
Reynolds John | Ireland
Rosati Riccardo | Italy
Roukos Dimitrios | Greece
Rouvelas Ioannis | Sweden
Roviello Franco | Italy
Savarino Edoardo | Italy
Schizas Dimitrios | Greece
Schroeder Wolfgang | Germany
Sgouros Spyridon | Greece
Siersema Peter | The Netherlands
Sioulas Athanasios | Greece

Stasinos Ioannis | Greece
Theodorou Dimitrios | Greece
Titcomb Dan | United Kingdom
Tutuian Radu | Switzerland
Tsoukali Emmanouela | Greece
Tzouvala Maria | Greece
Van Berge Henegouwen Mark | The Netherlands
Van der Peet Donald | The Netherlands
Van Hillegersberg Richard | The Netherlands
Van Lanschot Jan J. B. | The Netherlands
Varitimiadis Konstantinos | Greece
Vlachogiannakos Ioannis | Greece
Zaninotto Giovanni | United Kingdom
Ziogas Dimitrios | Greece
<table>
<thead>
<tr>
<th>Time</th>
<th>Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-08:30</td>
<td><strong>REGISTRATION</strong></td>
</tr>
<tr>
<td>08:30-16:30</td>
<td><strong>HALL B (MC 2)</strong></td>
</tr>
<tr>
<td><strong>PRE-COURSE I</strong></td>
<td>Surgical course – live videos in Minimally Invasive Esophagectomy</td>
</tr>
<tr>
<td>08:30-10.30</td>
<td><strong>MIE – Abdominal stage</strong></td>
</tr>
<tr>
<td></td>
<td>• Welcome (5mins)</td>
</tr>
<tr>
<td></td>
<td>• Anesthetic considerations in MIE (20mins)</td>
</tr>
<tr>
<td></td>
<td>• Power Point Presentations (20 mins):</td>
</tr>
<tr>
<td></td>
<td>- Abdominal anatomy</td>
</tr>
<tr>
<td></td>
<td>- Patient positioning</td>
</tr>
<tr>
<td></td>
<td>- Trocar placement</td>
</tr>
<tr>
<td></td>
<td>- Gastric dissection / Lymphadenectomy</td>
</tr>
<tr>
<td></td>
<td>- Conduit construction</td>
</tr>
<tr>
<td></td>
<td>• Live Videos (75 mins)</td>
</tr>
<tr>
<td></td>
<td>Abdominal stage of 2-stage MIE</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td><strong>COFFEE BREAK</strong></td>
</tr>
<tr>
<td>11.00-13.30</td>
<td><strong>MIE – Thoracic stage</strong></td>
</tr>
<tr>
<td></td>
<td>• Power Point Presentations (30 mins):</td>
</tr>
<tr>
<td></td>
<td>- Thoracic anatomy</td>
</tr>
<tr>
<td></td>
<td>- Patient positioning</td>
</tr>
<tr>
<td></td>
<td>- Trocar placement</td>
</tr>
<tr>
<td></td>
<td>- Esophageal dissection / Lymphadenectomy</td>
</tr>
<tr>
<td></td>
<td>- Conduit pull up</td>
</tr>
<tr>
<td></td>
<td>- Specimen extraction</td>
</tr>
<tr>
<td></td>
<td>- Intrathoracic Esophago-gastric Anastomosis</td>
</tr>
<tr>
<td></td>
<td>• Live Videos (120 mins):</td>
</tr>
<tr>
<td></td>
<td>- Thoracic stage of 2-stage MIE</td>
</tr>
<tr>
<td></td>
<td>- Intrathoracic esophagogastric anastomosis</td>
</tr>
<tr>
<td></td>
<td>- Hand-sewn</td>
</tr>
<tr>
<td></td>
<td>- Circular stapler</td>
</tr>
<tr>
<td></td>
<td>- Linear stapler</td>
</tr>
<tr>
<td></td>
<td>- Upper mediastinal lymphadenectomy and esophageal dissection</td>
</tr>
</tbody>
</table>
**LUNCH BREAK**

**Robinatic Esophagectomy & Pitfalls during MIE**

- **Power Point Presentations (20 mins):**
  - Docking
  - Patient positioning
  - Trocar placement
  - Esophageal dissection / Lymphadenectomy
  - Intrathoracic Esophago-gastric Anastomosis

- **Live Videos (100 mins):**
  - Thoracic stage of 2-stage MIE
  - Intrathoracic esophagogastric anastomosis
  - Pitfalls during MIE – tips & tricks

**PRE-COURSE I • Faculty**

Alexandros Charalabopoulos, Greece
Asif Chaudry, UK
Mark Van Berge Henegouwen, The Netherlands
Richard Van Hillegersberg, The Netherlands

Bruno Lorenzi, UK
David O’Hara, UK
Ioannis Rouvelas, Sweden
Dan Titcomb, UK
08:00-08:30  REGISTRATION

08:30-16:30  HALL C (MC 3)

PRE-COURSE II • Endoscopy Course – Hands-on-course

08:30-10:30
• Welcome (5mins)
• Hemostasis
• ESD/EMR
• Foreign body removal
• Motility (HRM, 24hrs pH-impedance, Bravo capsule)
• EUS

10:30-11:00  COFFEE BREAK

11.00-13.30
• Hemostasis
• ESD/EMR
• Foreign body removal
• Motility (HRM, 24hrs pH-impedance, Bravo capsule)
• EUS

13.30-14.30  LUNCH BREAK

14.30-16.30
• Hemostasis
• ESD/EMR
• Foreign body removal
• Motility (HRM, 24hrs pH-impedance, Bravo capsule)
• EUS

PRE-COURSE II • Faculty

Motility
Georgios Karamanolis
Pantelis Oustamanolakis
Anastasios Manolakis
Emmanouela Tsoukali

Hemostasis
Konstantina Paraskeva
Stavros Dimitriadis
Vasilios Papastergiou

EMR/ESD
Alexandros Kofokotsios
Ioannis Stasinos
Spyridon Michopoulos

Foreign Body Retrieval
Pantelis Karatzas

EUS
Ioannis Papanikolaou
Ioannis Kalliakmanis
Dimitrios Panagiotakopoulos
Konstantinos Varitimidis

IOANNIS VLACHOGIANNAKOS
SOTIRIOS GEORGOPoulos
THEODOROS EMMANOULI
ATHANASIOS SIOLAS
ANTONIOS KOLLOPOULOS
MARIA TZOUVALA

Ioannis Vlachogiannakos
Sotirios Georgopoulos
Theodoros Emmanouil
Athanasios Sioulas
Antonios Nikolopoulos
Maria Tzouvala

EMR/ESD
Alexandros Kofokotsios
Ioannis Stasinos
Spyridon Michopoulos

EUS
Ioannis Papanikolaou
Ioannis Kalliakmanis
Dimitrios Panagiotakopoulos
Konstantinos Varitimidis
17:00-18:00 REGISTRATION TO CONGRESS

18.00-19.30 HALL A (SKALKOTAS)

OPENING CEREMONY
Chairs: T. Liakakos, M. Nilsson

- Opening remarks from the ESDE President M. Nilsson
- Welcome from the 2019 ESDE Athens Congress President T. Liakakos
- Opening Lecture “Medicine & Surgery in Ancient Greece” S. Geroulanos

19.30 HALL A (SKALKOTAS)

CONCERT
“Music without borders”
Savina Yannatou (voice)
Kostas Grigoreas (guitar)

20.00 SKALKOTAS FOYER

WELCOME RECEPTION
08:00-10:30  REGISTRATION TO CONGRESS

08:30-10:00  HALL A (SKALKOTAS)

**Staging in esophageal cancer: Were are we heading?**

**Chairs:** T. Liakakos, J. Van Lanschot

- TNM 8th edition: What’s new and what are the clinical implications?  
  **L. Depypere**
- Clinical staging: Pitfalls, limitations and where do we go from here?  
  **D. Low**
- Staging by novel molecular subtypes with genome and transcription analysis  
  **D. Roukos**
- Important aspects of preoperative endoscopic evaluation of esophageal cancer  
  **M. Van Berge Henegouwen**
- Esophageal cancer clinical restaging after neoadjuvant therapy in 2019: State-of-the-art  
  **M. Nilsson**

10:00-10:30  COFFEE BREAK

10:30-12:00  HALL A (SKALKOTAS)

**Hot topics**

**Chairs:** M. Cuesta, R. Rosati

- Is esophageal cancer the next malignancy that should be considered for screening: what is the evidence  
  **P. Siersema**
- Endoscopic management of Barrett’s esophagus in the days of quality assessment  
  **I. Papanikolaou**
- Robotic esophageal surgery: State-of-the-art  
  **R. Van Hillegersberg**
• Results from the International Oesophago-Gastric Anastomosis Audit (OGAA)  
  E. Griffiths
• Immunotherapy: a panacea for the future?  
  A. Chaudry

12:00-13:00  HALL A (SKALKOTAS)

PLENARY SESSION I – The “Christophe Mariette” Lecture  
Chair: T. Lerut, M. Nilsson

Multimodality Treatment in esophageal cancer  
  J. Reynolds

13:00-14:00  LUNCH BREAK

14:00-15:30  HALL A (SKALKOTAS)

Oral presentations and discussion  
Chair: P. Grimminger, I. Rouvelas

01 Direct oral feeding following minimally invasive esophagectomy (NUTRIENT II trial): an international, multicenter, open-label randomized controlled trial  
  L. F. C. Fransen

02 Treatment of anastomotic leakage after esophagectomy (TENTACLE study)  
  M. Verstegen

03 Outcomes of Ivor Lewis versus McKeown oesophagectomy for cancer: a propensity score matched analysis of the Netherlands Cancer Registry  
  M. Verstegen

04 Non-radical esophagectomy for esophageal cancer; a nationwide study on incidence, risk factors and outcomes in Sweden  
  D. Edholm

05 Surveillance using FDG-uptake in the primary tumour on PET/CT in patients with oesophageal cancer and a clinically complete response after neoadjuvant chemoradiotherapy  
  M. J. Valkema
Tumor volume regression during neoadjuvant chemoradiotherapy for esophageal cancer: a prospective study with weekly MRI
I. L. Defize

Interval distant metastases during or after neoadjuvant chemoradiotherapy for esophageal or gastroesophageal junction cancer: a Nation-wide population-based cohort study
T.E. Kroese

TGF-beta1 and TGF-beta2 mediated epithelial-mesenchymal transition in esophageal adenocarcinoma cells
R. Thieme

E-cadherin expression correlates with progression of esophageal squamous cell carcinoma
H. Koda

Malnutrition indices as prognostic factors for postoperative complications in esophageal cancer patients
I. Lidoriki

15:30-16:00 COFFEE BREAK

16:00-17:30 HALL A (SKALKOTAS)

Optimizing outcomes in multimodality treatment of esophageal cancer
Chairs: L. Bonavina, D. Van der Peet

• Prehabilitation in esophageal cancer surgery
  K. Moorthy
• Neoadjuvant and perioperative therapy in current clinical practice
  M. Nilsson
• From CROSS to SANO trial. Is surgery always needed?
  J. van Lanschot
• When and why the FLOT-4 regiment?
  D. Ziogas
• 3-years results of the French MIRO trial
  G. Piessen

19:00 Departure from Megaron to Acropolis Museum & Congress Dinner (optional)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-10:30</td>
<td>Registration to Congress</td>
</tr>
<tr>
<td>08:30-10:00</td>
<td>Oral presentations and discussion</td>
</tr>
</tbody>
</table>

**Chairs:** A. Kechagias, D. Schizas

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>Giant esophageal polyp protruding through the mouth: a rare case</td>
<td>K. Dinaki</td>
</tr>
<tr>
<td>02</td>
<td>Esophageal motility of lung transplant recipients diagnosed with systemic connective tissue disorder: a single-center experience</td>
<td>M. Csucska</td>
</tr>
<tr>
<td>03</td>
<td>A propensity score-matched case-control study to compare POEM and laparoscopic Heller myotomy in the treatment of esophageal achalasia</td>
<td>A. Costantini</td>
</tr>
<tr>
<td>04</td>
<td>Quality of life for achalasia patients is the same after per-oral endoscopic myotomy (POEM) and Heller myotomy</td>
<td>G. Z. Poulou</td>
</tr>
<tr>
<td>05</td>
<td>The association of perioperative quality-of-care parameters (textbook outcome) with long term outcome after esophagectomy for esophageal cancer</td>
<td>MC Kalff</td>
</tr>
<tr>
<td>06</td>
<td>A chemoradiotherapy treatment response MRNA signature as predictor for esophageal adenocarcinoma treated according to the CROSS regimen</td>
<td>K. K. Krishnadath</td>
</tr>
<tr>
<td>07</td>
<td>Lasting symptoms after esophageal resection (LASER) – European multi-center cross-sectional study</td>
<td>S. Markar</td>
</tr>
<tr>
<td>08</td>
<td>Minimally invasive oesophagectomy: a long learning curve for better oncological resection and improved survival outcome</td>
<td>F. Di Maggio</td>
</tr>
<tr>
<td>09</td>
<td>Anastomotic techniques and associated morbidity in total minimally-invasive transthoracic esophagectomy – results from the esobenchmark database</td>
<td>W. Schroeder</td>
</tr>
<tr>
<td>10</td>
<td>10-year follow-up of a randomised controlled trial comparing neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS)</td>
<td>B. M. Eyck</td>
</tr>
</tbody>
</table>
10:00-10:30  COFFEE BREAK

10:30-12:00  HALL B (MC 2)

Barrett’s esophagus
Chairs: G. Karamanolis, R. Tutuian

- Definition, classification and surveillance of Barrett’s esophagus  
  R. Penagini
- Molecular markers for progression to dysplasia and adenocarcinoma  
  M. Gazouli
- Endoscopic treatment  
  S. Michopoulos
- Optimal prevention of progression from GERD to cancer  
  - The gastroenterologist’s view | J. Vlahogiannakos  
  - The surgeon’s view | D. Theodorou

12:00-13:00  PLENARY SESSION I in HALL A (SKALKOTAS)

13:00-14:00  LUNCH BREAK

14:00-15:30  HALL B (MC 2)

GERD – Refractory GERD
Chairs: P. Siersema, D. Titcomb

- State-of-the-art: Diagnostic methods in GERD  
  E. Savarino
- Refractory GERD: Subtypes, pathophysiology and therapy  
  R. Tutuian
- More than thirty years experience with the use of proton pump inhibitors  
  A. Manolakis
- Endoscopic management. Indications and limitations  
  A. Kofokotsios
- The optimal surgical procedure for reflux disease. When and how?  
  L. Lundell
<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Authors/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30-16:00</td>
<td>COFFEE BREAK</td>
<td></td>
</tr>
<tr>
<td>16:00-17:30</td>
<td>Oral presentations and discussion</td>
<td>Chairs: M. Van Berge Henegouwen, O. Lyros</td>
</tr>
<tr>
<td></td>
<td><strong>01</strong> Diaphragmatic hernia after Ivor-Lewis oesophagectomy: analysis of risk factors and surgical repair results</td>
<td>P. Parise</td>
</tr>
<tr>
<td></td>
<td><strong>02</strong> Meta-analysis of prognostic factors for overall survival in patients undergoing oesophagectomy for oesophageal cancers</td>
<td>E. J. Marson</td>
</tr>
<tr>
<td></td>
<td><strong>03</strong> Microanatomy based standardization of left upper mediastinal lymph node dissection in thoracoscopic esophagectomy in the prone position</td>
<td>Y. Shirakawa</td>
</tr>
<tr>
<td></td>
<td><strong>04</strong> Gastric conduit necrosis after esophagectomy: risk prediction, management and outcomes</td>
<td>A. van der Veen</td>
</tr>
<tr>
<td></td>
<td><strong>05</strong> Adjuvant chemoradiotherapy is beneficial in margin positive patients following neo-adjuvant chemotherapy and surgery for lower oesophageal and GOJ adenocarcinoma</td>
<td>R. Bott</td>
</tr>
<tr>
<td></td>
<td><strong>06</strong> Worldwide Techniques and Outcomes of Robot-assisted Minimally Invasive Esophagectomy (RAMIE): Results from the International UGIRA Registry</td>
<td>B. F. Kingma</td>
</tr>
<tr>
<td></td>
<td><strong>07</strong> Finding factors associated with safe implementation of Ivor Lewis totally minimally esophagectomy</td>
<td>L. Claassen</td>
</tr>
<tr>
<td></td>
<td><strong>08</strong> Calcification in the descending aorta predicts postoperative leakage of intra-thoracic anastomosis after esophagectomy for cancer</td>
<td>A. Kechagias</td>
</tr>
</tbody>
</table>
Serum C-reactive protein can be an early predictor of length of stay after minimally invasive oesophagectomy
G. Corsi

Short-term results of a randomized controlled trial of standard vs. prolonged time to surgery after neoadjuvant chemoradiation for cancer
K. Nilsson

17:45-18:45  HALL B (MC 2)

ESDE Business Meeting

19:00  Departure from Megaron to Acropolis Museum & Congress Dinner (optional)
08:00-10:30 REGISTRATION TO CONGRESS

08:30-10:00 HALL A (SKALKOTAS)

Surgical strategies for esophageal cancer
Chairs: A. Chaudry, P. Nafteux

- Overview of types of open and minimal invasive resections
  R. Rosati
- Positioning and extent of resection in MIE. The upper paratracheal nodal dissection challenge
  L. Bonavina
- MIE. The difficult intrathoracic anastomosis
  A. Charalabopoulos
- New robotics and artificial intelligence in esophageal cancer surgery
  P. Grimminger

10:00-10:30 COFFEE BREAK

10:30-12:00 HALL A (SKALKOTAS)

Joint session with IGCA
Chairs: M. Griffin, W. Schroeder

- Molecular biology in EGJ cancer: Does it affect surgical decision making?
  I. Gockel
- Adjunct oncological therapy in juctional adenocarcinoma
  M. Karamouzis
- Role of Minimally Invasive Surgery in Siewert III Cancers
  G. De Manzoni
- Optimal resection and extend of lymphadenectomy in Siewert II cancers
  - IGCA View | F. Roviello
  - ESDE View | R. van Hillegersberg
Difficult cases and a step forward?
Chairs: A. Charalabopoulos, M. Pera

- Surgical resection of locally advanced T4b tumors
  W. Schroeder
- Esophagectomy with unavailable gastric conduit
  T. Liakakos
- Surgery for oligometastatic Disease
  S. Moenig

Complications post esophagectomy
Chairs: A. Botha, M. Nilsson

- Preemptive measures to avoid serious leaks
  M. Cuesta
- Endoscopic management of anastomotic leaks
  M. Lindblad
- Tracheo-esophageal fistula after esophageal resection: scope
  of the problem and current management
  D. Van der Peet
- Conduit related problems
  M. Pera
- Management of chylothorax
  I. Rouvelas
### PLENARY SESSION II

**Chairs:** G. Hanna, G. Zaninotto

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-17:00</td>
<td>Young investigators meeting – Dragons Den</td>
<td>S. Markar</td>
</tr>
<tr>
<td>17:00-17:15</td>
<td>The UMC Utrecht, ESDE-MIE fellowship program</td>
<td>R. Van Hillegersberg</td>
</tr>
<tr>
<td>17:15-17:30</td>
<td>Meet the Editor of DOTE</td>
<td>G. Zaninotto</td>
</tr>
</tbody>
</table>

### CLOSING REMARKS

**Speakers:** T. Liakakos, M. Nilsson

17:30
 Oral presentations and discussion
Chairs: I. Karavokyros, A. Kechagias

01 Lyon consensus criteria significantly changes the PH impedance diagnosis of gastroesophageal reflux disease (GERD)
A. Ioannou

02 A slightly crazy but informative experiment of the effect of the head down posture on the characteristics of oesophageal motility and oesophagogastric junction using High resolution oesophageal manometry
B. Nagammapudur

03 Computed Tomography can predict outcomes after caustic injury ingestion?
J. Weindelmayer

04 Twenty-five years of laparoscopic treatment for esophageal achalasia: our experience on 1001 laparoscopic Heller-Dor operations
R. Salvador

05 Genomic biomarkers for cancer risk in Barrett’s esophagus: an update on the longitudinal Dutch Barrett’s esophagus cohort
K. K. Krishnadath

06 Classification of Barrett’s carcinoma specimens by hyperspectral imaging (HSI)
R. Thieme

07 Very long-term (5-19 years) follow-up paraesophageal hernia repair: permanent mesh vs standard cruroplasty
M. Pamela

08 The epidemiology of anti-reflux surgery in Denmark 2000-2017: a nationwide registry-based population study
J. S. Ljungdalh

09 Role of malnutrition in oesophageal surgery for cancer
R. Alfieri
Ivor Lewis esophagectomy after sleeve gastrectomy: the use of gastric conduit is still possible
G. Pallabazzer

Esophagectomy for esophageal cancer in an Upper GI unit of the National and Kapodistrian University of Athens during the period 2004-2019
K. Mylonas

10:00-10:30  COFFEE BREAK

10:30-12:00  HALL B (MC 2)

Facing Achalasia
Chairs: D. Schizas, G. Karamanolis

- Manometry in achalasia: Novel tools
  P. Oustamanolakis
- Current trends in the management of achalasia
  - The optimal surgical approach – HELLER operation | A. Alexandrou
  - The endoscopic approach – POEM | G. Mavrogenis
- Is GERD following achalasia treatment a problem?
  T. Emmanouil
- Failed Heller & recurrence of dysphagia
  I. Karavokyros

12:00-13:00  HALL B (MC 2)

Paraesophageal hernias
Chairs: L. Bonavina, D. Titcomb

- Work up and surgical indications
  D. Dellaportas
- Technical aspects of the optimal repair
  B. Lorenzi
- Dealing with the failed repair
  A. Botha
13:00-14:00  
**LUNCH BREAK**

14:00-15:30  📍 HALL B (MC 2)

**Challenging cases**  
Chairs: K. Moorthy, I. Papanikolaou

- Management of refractory esophageal strictures  
  K. Paraskeva
- Boerhaave syndrome  
  O. Lyros
- Hiatal hernia with motility disorders  
  D. Schizas
- Esophageal foreign bodies  
  I. Stasinos
- Eosinophilic esophagitis  
  S. Sgouros

15:30-16:00  
**COFFEE BREAK**

16:00-17:30  📍 PLENARY SESSION in HALL A (SKALKOTAS)
posters
4. Fulminant cerebral air embolism following endovac-therapy in esophageal anastomotic leakage – A rare complication
   Jonas Herzberg, Germany

5. Feasibility and efficacy of Indocyanine green Angiography during Esophago-gastrectomy: A systematic review
   Hanne Vanommeslaeghe, Belgium

6. Hiatal hernia repair by tension-free mesh closure or simple suturing of the diaphragmatic hiatus
   Apostolos Analatos, Sweden

7. The impact of prehabilitation on parameters of body composition in patients undergoing multimodal therapy for oesophago-gastric (OG) cancer
   Emre Doganay, United Kingdom

8. Keratin 17 promotes cells proliferation and metastasis in esophageal squamous cell carcinoma
   Zhun Liu, China

11. KRT17 promotes proliferation and metastasis of esophageal squamous cell carcinoma leading to poor prognosis
    Zhun Liu, China

12. Long-term quality of life after total gastrectomy versus Ivor Lewis esophagectomy
    Egle Jezerskyte, The Netherlands

13. Difference in long-term quality of life between McKeown and Ivor Lewis esophagectomy
    Egle Jezerskyte, The Netherlands

14. The impact of transthoracic and transhiatal esophagectomy on long-term quality of life according to EORTC QLQ-C30 and EORTC QLQ-OG25 questionnaires
    Egle Jezerskyte, The Netherlands

    Christian A. Gutschow, Switzerland

20. Minimally invasive treatment of chyle leak after esophagectomy using indocyanine green (ICG) enhanced fluorescence
    Luca Alberti, Italy

    Carlo Alberto De Pasquale, Italy

22. Preliminary Experience with Prophylactic Thoracic Endovascular Aortic Repair (Pro-TEAVAR) in Patients Affected by Advanced Esophageal Cancer
    Maria Clelia Gervasi, Italy

24. Treatment for Recurrent Esophageal Squamous Cell Carcinoma after Curative Esophagectomy
    Hiroshi Okamoto, Japan

25. Detection of circulating tumor cells in potentially resectable adenocarcinoma of the distal esophagus and the gastro-esophageal junction is not increased in portal venous blood samples compared to peripheral venous blood samples
    Lieven Depypere, Belgium

27. Peroral endoscopic myotomy (POEM) for treatment of achalasia. Clinical outcomes of a single-center institute in UK
    Gavriella Zoi Vrakopoulou, Greece

28. An open transthoracic esophagectomy results in higher postoperative c-reactive protein levels compared to minimally invasive esophagectomy
    Benjammin Babic, Germany

29. Comparison between minimally invasive and open esophagectomy in patients aged ≥75 years: a nationwide propensity-score matched cohort study
    Nikolaj Baranov, The Netherlands

31. Surgical management of acquired tracheoesophageal fistula caused by esophageal diverticulum
    Yifeng Sun, China
33 Upper esophageal sphincter (UES) abnormalities are significant diagnostic findings in patients with atypical GERD underwent pH-impedance and High Resolution Manometry (HRM)
Alexandros Ioanou, Italy

35 Gastroesophageal reflux disease (GERD) after bariatric surgery – Exploring the pathophysiological mechanisms around the Oesophagogastric junction
Nagammapudur Balaji, United Kingdom

36 De novo GORD after Roux Y Gastric Bypass: Uncommon but possible – A look at the WHY factors
Hatem Al-Saadi, United Kingdom

37 Limited mediastinal lymphadenectomy for elderly patients over 75 years old with thoracic esophageal carcinoma is permissible
Naoto Ujiie, Japan

38 Resection margins after oncological esophagectomy; does the definition of the R status matter?
Pénélope St-Amour, Switzerland

39 Chyloptysis after esophagectomy for esophageal cancer; a rare complication
Saana Andersson, Finland

40 Conditional survival after curative treatment of esophageal cancer
Eliza R.C. Hagens, The Netherlands

41 C-reactive protein as a predictor for anastomotic leakage after esophageal surgery
Eliza Hagens, The Netherlands

42 Efficacy of endoscopic treatment for contained leakage after Ivor Lewis esophagectomy
Merel Lubbers, The Netherlands

43 Is there an optimal definition for positive circumferential resection margin in locally advanced oesophageal cancer?
Brac Baptiste, France

44 The extent and consequences of lymphadenectomy in esophageal cancer surgery: a case vignette survey
Didi.J.J.M. De Gouw, The Netherlands

45 Transthoracic versus Transhiatal esophagectomy for esophageal cancer: a nation- wide propensity score matched cohort analysis
Marianne Kalff, The Netherlands

46 A prediction model of hospital stay after esophagectomy within an Enhanced Recovery After Surgery (ERAS) pathway
Paolo Parise, Italy

48 Mediastinoscopy-assisted esophagectomy for an upper thoracic squamous cell carcinoma in a patient with liver cirrhosis
Zohra Faiz, The Netherlands

49 Hiatal hernia >3cm is associated with worse response to neoadjuvant treatment in esophageal cancer patients
Styliani Mantziari, Switzerland

51 Nutritional deficiency post oesophagogastric surgery in cancer patients
Arun Ariyarathenam, United Kingdom

52 Liver reduction diet in patients undergoing gastro-oesophagectomies
Arun Ariyarathenam, United Kingdom

53 Minimally Invasive Techniques for Transthoracic Esophagectomy for Esophageal Cancers: A Systematic Review and Network Meta-Analysis
Kwabena Siaw-Acheampong, United Kingdom

54 Incidence and outcome of hiatal hernia after oesophagectomy: comparison of traditional open and minimally invasive approach
Jonas Sanberg Ljungdalh, Denmark

57 Motility disorders of the esophagus - A risk factor for the development of Barrett’s esophagus?
Laura Knepper, Germany

58 Impact of systematic enteral nutrition in oesophageal or oesogastric junction (OG) cancers involved in a curative strategy
Hélène Marin, France

59 Predictors for anastomotic leakage after esophagectomy and impact on survival
Eliza Hagens, The Netherlands

60 Critical Appraisal of Gastric Conduit Ischaemic Conditioning prior to Oesophagectomy: A Systematic Review and Meta-Analysis
Sivesh Kamarajah, United Kingdom

61 Cardiac tamponade - a serious complication after colon conduit interposition: a case report
Silvia Jarosciakova, Czech Republic

62 Risk Factors and Outcomes Associated with Anastomotic Leaks (AL) following Oesophagectomy: A Systematic Review and Meta-Analysis
Aaron Lin, United Kingdom
| 63 | Requirements for a new diagnostic test to detect lymph node metastases in esophageal cancer: A health-economic modelling study | Mirre Scholte, The Netherlands |
| 65 | USPIO-MRI for pre-operative lymph node staging after neoadjuvant chemoradiotherapy: feasibility and validation framework | Didi De Gouw, The Netherlands |
| 66 | ENSURE: European investigation of Surveillance after Resection for Esophageal cancer | Dr. Jessie Elliott, Ireland |
| 67 | Semimechanical anastomosis during esophagectomy: a new gold standard? | Elena Mazza, Italy |
| 68 | Definitive results of the Heller myotomy associated with the Dor fundoplication performed with intraoperative manometry for the primary surgical treatment of esophageal achalasia: one center experience | Valentina Tassi, Italy |
| 69 | Intraoperative endoscopy is of great importance in complex revisional upper GI surgery. Case presentation of recurrent achalasia previously treated with 3 laparoscopic hellers cardiomyotomies | Abraham Botha, United Kingdom |
| 73 | Contribution to the improvement of cardiac load by radical surgery for advanced esophageal hiatal hernia | Shunsuke Tanabe, Japan |
| 74 | A Systematic Review and Network Meta-Analysis of Anastomotic Techniques for Oesophagectomy for Malignancy | Sivesh K Kamarajah, United Kingdom |
| 75 | Critical Appraisal of the Impact of Oesophageal Stents in the Management of Oesophageal Anastomotic Leaks and Benign Oesophageal Perforations: An Updated Systematic Review | Sivesh Kamarajah, United Kingdom |
| 77 | Significance of neoadjuvant downstaging in carcinoma of the esophagus and gastro-esophageal junction | Sivesh Kamarajah, United Kingdom |
| 78 | Critical Appraisal of the Impact of Surgical Repair of Type II - IV Paraesophageal Hernia on Pulmonary Improvement: A Systematic Review and Meta-Analysis | Sivesh Kamarajah, United Kingdom |
| 79 | Critical Appraisal on the Impact of Smoking Status on Perioperative Morbidity, Mortality and long-term Survival following Oesophagectomy for Oesophageal Cancers: A Tertiary Unit Analysis | Sivesh Kamarajah, United Kingdom |
| 80 | Long-term outcomes of clinical and pathological-staged T3N3 esophageal cancer | Sivesh Kamarajah, United Kingdom |
| 81 | Impact of lymphadenectomy on survival after unimodality transthoracic esophagectomy for adenocarcinoma of the esophagus | Kiera Hardy, United Kingdom |
| 85 | Quantification of intraoperative fluorescence angiography to assess anastomotic perfusion during gastro-intestinal surgery: a systematic review | Maxime D. Slooter, The Netherlands |
| 86 | Combined endoscopic and surgical procedure for excision of a giant fibrovascular polyp | Tessa Fraser, United Kingdom |
| 87 | Fluorescence angiography of the anastomotic site during esophagectomy: time to enhancement as quantitative value to predict anastomotic leakage | Maxime D. Slooter, The Netherlands |
| 91 | Pharyngo-Oesophageal perforation following cervical spine surgery: a single centre experience | Lucia Moletta, Italy |
| 93 | BELSEY MARK IV: still a valid option. Single center experience of 100 consecutive cases | Sander Ovaere, Belgium |
95 Laparoscopic assisted left thoraco-abdominal oesophagectomy (LLTA); an innovative approach for tumours of the gastro-oesophageal junction
Arasteh Reyhani Calvo, United Kingdom

96 The Current Role of Adjuvant Therapy in Patients following Neo-Adjuvant Chemotherapy and R0 Resection for Lower Oesophageal and GOJ Adenocarcinoma
Rebecca Bott, United Kingdom

98 Unsaturated lipids are significantly upregulated in Oesophageal Adenocarcinoma
Pranav Patel, United Kingdom

99 A Structured Training Pathway to Implement Robot-Assisted Minimally Invasive Esophagectomy (RAMIE): Learning Curve Results from a High Volume Center
Feike Kingma, The Netherlands

101 The impact of paratracheal lymphadenectomy on lymph node yield and short-term outcomes in esophagectomy: a national propensity score matched analysis
Feike Kingma, The Netherlands

103 A hand-sewn intrathoracic anastomosis in robot-assisted minimally invasive esophagectomy (RAMIE): a detailed description of technique and outcomes
Eline De Groot, The Netherlands

113 Esophagectomy-specific Objective Structured Assessment of Technical Skill (E-OSATS): consensus on essential Ivor-Lewis and McKeown steps trough Delphi methodology
Yassin Eddahchouri, The Netherlands

115 Transition from oesophagectomy to endoscopic therapy for early oesophageal cancer – a single centre experience of 251 consecutive cases
Arasteh Reyhani Calvo, United Kingdom

116 A pilot study on energy intake and total energy expenditure, using a multi sensor device, in oesophageal cancer patients during the entire course of modern multimodality treatment
Jessica Ericson, Sweden

121 Esophagectomy-specific Objective Structured Assessment of Technical Skill (E-OSATS): validation protocol
Yassin Eddahchouri, The Netherlands

124 Localized esophageal neuroendocrine tumors. Report on clinical and treatment parameters from a tertiary hospital
Jose Duran-Moreno, Greece

127 Trends in clinicopathological data of esophageal cancer in Greece. A single center’s experience
Jose Duran-Moreno, Greece

131 Revealing the ergonomic crisis of an upper gastrointestinal robotic surgeon – still a lot to improve in minimally invasive surgery
Hans F. Fuchs, Germany

132 Laryngopharyngeal pH Monitoring (Restech) may predict a successful surgical outcome for regurgitation and oropharyngeal symptoms after laparoscopic antireflux surgery
Hans Fuchs, Germany

137 Outcome of patients undergoing Endoscopic Mucosal Resection for Cancer of the Oesophagus from a single centre
Jakub Chmelo, United Kingdom

140 Laparoscopic Modified Belsey type fundoplication for reflux after Roux Y gastric bypass – A potential saviour when the saviour is in trouble!
Hatem Al-Saadi, United Kingdom

145 Optimal perioperative pain management in esophageal surgery
Minke Feenstra, The Netherlands

146 An Improvement to the Circular Stapling Anastomosis Technique during Minimally Invasive Ivor Lewis Procedure
Giovanni Capovilla, Italy

195 The structure of a consultation hour for benign diseases of the upper gastro-intestinal tract at a centre of excellence for esophageal and gastric surgery
Laura Knepper, Germany

197 Long-Term Health-related Quality of Life after Benign Esophageal Perforation
Laura Knepper, Germany

204 Detecting pathological complete response in esophageal cancer after neoadjuvant therapy based on imaging techniques: a diagnostic systematic review and meta-analysis
Richard ten Broek, The Netherlands

215 The Complex Benign Upper GI MDT - A quality improvement initiative from a tertiary centre
Syed Raza, United Kingdom
Severe dumping symptoms are uncommon following transthoracic esophagectomy but significantly decrease health-related quality of life in long-term, disease free survivors
Fredrik Klevebro, Sweden

Nutritional jejunostomy in esophagectomy for cancer, a national register-based cohort study of associations with postoperative outcomes and survival
Fredrik Klevebro, Sweden

Is open left thoraco-abdominal esophagectomy a viable option in the era of minimally invasive esophagectomy?
Fredrik Klevebro, Sweden

Localization of undetected residual tumor after neoadjuvant chemoradiotherapy in patients with esophageal cancer
Berend J. Van Der Wilk, The Netherlands

Extending myotomy both downwards and upwards improves the final outcome in manometric pattern III achalasia patients
Lucia Moletta, Italy

Traction of the septum during transoral septotomy in patient with Zenker diverticulum
Luca Provenzano, Italy

Selective lymphatic embolization to manage severe postoperative lymphatic leak
Gustav Linder, Sweden

miRNA483-3p and miRNA221 dysregulation and correlation with survival in esophageal adenocarcinoma (EAC)
Federica Isidori, Italy

Prediction of a positive circumferential resection margin in adenocarcinoma of the esophagus
William Knight, United Kingdom

Geographical differences in resection rates associated with survival in Sweden—is surgery underused?
Gustav Linder, Sweden

Management of liver oligometastatic esophageal cancer: review of the current indications and proposal for a multimodality strategy
Pietro Riva, Italy

Robotic-assisted repair of iatrogenic left bronchus perforation during RAMIE – a case report
Carolina Mann, Germany

The impact of elderly on surgical outcomes after Ivor-Lewis esophagectomy: review of a single institution experience
Andrea Cossu, Italy

Loss of SMAD4 expression in esophageal adenocarcinoma (EAC) is correlated to poor survival
Federica Isidori, Italy

Surgical outcomes after esophagectomy in the elderly population - a single center cohort study
Henna Söderström, Finland

Multimodal therapy in esophageal cancer beyond clinical trial: single centre experience
Simone Giacopuzzi, Italy

Robot assisted minimally invasive esophagectomy (RAMIE4) with intra-thoracic anastomosis: promising results and lessons learned in 100 patients
Evangelos Tagkalos, Germany

High esophagotracheal fistula during stent treatment of an anastomotic leakage after esophagectomy
Evangelos Tagkalos, Germany

Histone deacetylases expression and activity in esophageal adenocarcinoma cells in vitro
René Thieme, Germany

Intrathoratic anastomosis in Ivor-Lewis esophagectomy: technical description and results
Miriam Menéndez, Spain
134  Nasogastric tube utilization in patients undergoing esophagectomy: an unnecessary procedure  
Miriam Menéndez, Spain

136  Comparison of Totally Minimally and Hybrid Ivor Lewis esophagectomy for cancer of distal esophagus and esophagogastric junction  
Stefano De Pascale, Italy

138  Impact of neoadjuvant FLOT chemo-therapy on cardiorespiratory reserve of patients with oesophagogastric adenocarcinoma  
Jakub Chmelo, United Kingdom

139  Chyle Leak following Radical en-Bloc Oesophagectomy with 2 Field Nodal Dissection: Predisposing factors, Management and Outcomes  
Pamela Milito, United Kingdom

141  Ivor Lewis minimally invasive esophagectomy for esophageal cancer: impact of thoracoscopic on postoperative morbidity  
Louis Martin, France

142  Impact of neo-adjuvant chemotherapy on cardiorespiratory reserve, sarcopenia and quality of life in oesophago-gastric carcinoma  
Maziar Navidi, United Kingdom

147  Is hybrid minimally invasive esophagectomy safe for Siewert type II oesogastic junction tumors?  
Simon Gabriel, France

149  Minimal Invasive Temporary Gastric Electro Stimulation - 1 Year Follow  
Florian Corvinus, Germany

150  Ulcerating CMV esophagitis – a unique complication of Achalasia  
Florian Corvinus, Germany

151  Never smoker with esophageal squamous-cell carcinoma: different demographics but comparable survival  
Thibault Voron, France

152  Clinical predictive model of lymph node metastasis at right recurrent laryngeal nerve zone in esophageal squamous cell carcinoma  
Zhigang Li, China

155  Real-time evaluation of the gastric conduit based on the regional O2 saturation (%) and Total hemoglobin index in thoracic esophagectomy  
Takeo Fujita, Japan

156  Assessment of health related quality of life and digestive symptoms in long-term disease free survivors after esophagectomy  
Piers Boshier, United Kingdom

157  Giant pedunculated oesophageal liposarcomas: A case and review of resection techniques  
Andrew Wong, Singapore

158  Results of a national survey about perioperative care in gastric resection surgery  
Marcos Bruna, Spain

162  Enhanced Recovery Protocol compliance and clinical outcomes in esophagectomy for cancer: design of a measuring instrument  
Johnny Moons, Belgium

163  Outcomes of distal pancreatectomy and splenectomy during 2-stage esophagectomy for cancer  
Athanasios Syllaios, Greece

164  Esophageal perforations. Fighting between time, severity and individualization: a collective interhospital Upper GI Unit experience  
Athanasios Syllaios, Greece

166  Spontaneous esophageal rupture – Boerhaave syndrome  
Bogdan Movchan, Ukraine

167  Minimally-invasive 3-stage esophagectomy for cancer with colonic interposition: the initial experience in a tertiary center  
Ilias Vagios, Greece

169  Comparison of laparoscopic toupet fundoplication and magnetic sphincter augmentation in patients with 3-5 cm hiatus hernia  
Veronica Lazzari, Italy

170  Corrosive injury of the upper gastrointestinal tract: Laparoscopic total gastrectomy as a late repair treatment  
Spyridon Davakis, Greece
171 Laparoscopic repair of a giant Morgagni’s hernia presenting with respiratory distress
Spyridon Davakis, Greece

172 Esophageal submucosal lipoma and concomitant ineffective motility: laparoscopic transhiatal enucleation
Daniele Bernardi, Italy

173 High-resolution manometric findings after magnetic sphincter augmentation
Carlo Galdino Riva, Italy

174 Esophageal cancer surgery: experiences with anastomotic leak treatments at a high-volume center
Michael Hareskov Larsen, Denmark

175 Translation of minimally invasive esophagectomy from randomized controlled trial setting (TIME) to national practice (DUCA) in Netherlands
Sheraz Markar, United Kingdom

176 Micronutrient deficiencies following minimal invasive esophagectomy for cancer
Thijs Janssen, The Netherlands

177 Reinforced crural repair for large hiatus hernia: preliminary results with PHASIX ST® MESH
Tommaso Panici Tonucci, Italy

178 Synchronous triple cancer of the esophagus, gastric cardia and GIST of the stomach: a case report and review of the literature
Maria Christin Czubba, Germany

179 Thoracoscopic extended 2-field lymph node dissection for esophageal cancer
Implementation and surgical technique
Eleandros Kyros, Greece

180 Optimizing upper mediastinal lymphadenectomy during minimally invasive oesophagectomy in prone position: from 2D thoracoscopy and double lumen (DL) endotracheal tube ventilation to 3D thoracoscopy and single lumen (SL) tube ventilation
Bruno Lorenzi, United Kingdom

181 3D technology in minimally invasive Upper GI surgery: comparison between different systems
Bruno Lorenzi, United Kingdom

182 Esophageal submucosal lipoma and concomitant ineffective motility: laparoscopic transhiatal enucleation
Daniele Bernardi, Italy

183 High-resolution manometric findings after magnetic sphincter augmentation
Carlo Galdino Riva, Italy

184 Esophageal cancer surgery: experiences with anastomotic leak treatments at a high-volume center
Michael Hareskov Larsen, Denmark

185 Translation of minimally invasive esophagectomy from randomized controlled trial setting (TIME) to national practice (DUCA) in Netherlands
Sheraz Markar, United Kingdom

186 Micronutrient deficiencies following minimal invasive esophagectomy for cancer
Thijs Janssen, The Netherlands

187 Reinforced crural repair for large hiatus hernia: preliminary results with PHASIX ST® MESH
Tommaso Panici Tonucci, Italy

188 Synchronous triple cancer of the esophagus, gastric cardia and GIST of the stomach: a case report and review of the literature
Maria Christin Czubba, Germany

189 Thoracoscopic extended 2-field lymph node dissection for esophageal cancer
Implementation and surgical technique
Eleandros Kyros, Greece

190 Optimizing upper mediastinal lymphadenectomy during minimally invasive oesophagectomy in prone position: from 2D thoracoscopy and double lumen (DL) endotracheal tube ventilation to 3D thoracoscopy and single lumen (SL) tube ventilation
Bruno Lorenzi, United Kingdom

191 3D technology in minimally invasive Upper GI surgery: comparison between different systems
Bruno Lorenzi, United Kingdom

192 Esophageal submucosal lipoma and concomitant ineffective motility: laparoscopic transhiatal enucleation
Daniele Bernardi, Italy

193 High-resolution manometric findings after magnetic sphincter augmentation
Carlo Galdino Riva, Italy

194 Esophageal cancer surgery: experiences with anastomotic leak treatments at a high-volume center
Michael Hareskov Larsen, Denmark

195 Translation of minimally invasive esophagectomy from randomized controlled trial setting (TIME) to national practice (DUCA) in Netherlands
Sheraz Markar, United Kingdom

196 Micronutrient deficiencies following minimal invasive esophagectomy for cancer
Thijs Janssen, The Netherlands

197 Reinforced crural repair for large hiatus hernia: preliminary results with PHASIX ST® MESH
Tommaso Panici Tonucci, Italy

198 Synchronous triple cancer of the esophagus, gastric cardia and GIST of the stomach: a case report and review of the literature
Maria Christin Czubba, Germany

199 Thoracoscopic extended 2-field lymph node dissection for esophageal cancer
Implementation and surgical technique
Eleandros Kyros, Greece

200 Optimizing upper mediastinal lymphadenectomy during minimally invasive oesophagectomy in prone position: from 2D thoracoscopy and double lumen (DL) endotracheal tube ventilation to 3D thoracoscopy and single lumen (SL) tube ventilation
Bruno Lorenzi, United Kingdom

201 3D technology in minimally invasive Upper GI surgery: comparison between different systems
Bruno Lorenzi, United Kingdom

New method of esophagogastric anastomosis within minimally invasive hybrid Ivor Lewis procedure
Andrii Klimas, Ukraine

Multi-modal prehabilitation during neoadjuvant therapy prior to resection for oesophagogastric cancer: A pilot randomised controlled trial
Sophie Allen, United Kingdom

Carotid-gastroplasty fistula: an uncommon cause of hematemesis in the delayed postoperative period after esophagectomy
Luís Hurtado Pardo, Spain

Quality Assurance of Surgical Intervention within Randomized Controlled Trials for Gastro-oesophageal Reflux Disease
Sara Jamel, United Kingdom

Predictors of Barrett’s oesophagus progression: where are we?
Sara Jamel, United Kingdom

Minimally-invasive esophagectomy in treatment for esophageal diseases
Georgiy Savenko, Ukraine

CROSS regimen for adenocarcinoma of the esophagus and cardia: Does pathological response influence overall and disease free survival? Multicenter retrospective analysis
Stefano De Pascale, Italy

Superior polar gastrectomy associated with anti-reflux technique: case report
Ana Navio Seller, Spain

Is routine ICU admission necessary after transthoracic esophagectomy for esophageal and esophagogastric junction cancer?
Andrea Pansa, Italy

Laparoscopic transhiatal omental repair of iatrogenic esophageal perforation in achalasia
Martina Nebbia, Italy
202 Esophageal variceal banding ligation: Six-year experience of a tertiary center
Ioannis Papanikolaou, Greece

203 Pharyngoesophageal reconstruction after laryngectomy and radiotherapy
Spyridon Stavrianos, Greece

205 Three years experience of the first specialized esophageal center in Egypt
Reda Ezz, Egypt

206 Evaluation of preemptive multimodal analgesia in Ivor Lewis esophagectomy
Polyxeni Doka, Greece

207 Comparison of opioid VS opioid plus local anesthetic epidural administration in Ivor Lewis esophagectomy
Polyxeni Doka, Greece

208 Paravertebral catheter analgesia for minimally invasive Ivor Lewis oesophagectomy
E. Cheong, United Kingdom

209 Oesophageal disruptions - A multidisciplinary algorithmic approach
Renol Koshy, United Kingdom

210 Hybrid Laparoscopic Robot-assisted Minimally-invasive Esophagectomy: a prospective experience in a Referral Center
Stefano Santi, Italy

211 Comparison of prognostic value for G8 screening tools with fTRST in older patients of esophageal cancer
Masayoshi Terayama, Japan

213 Prognostic Significance of Changes in Lymph Node morphology on Survival in Esophageal Cancer after Neoadjuvant therapy: A Systematic Review and Meta-Analyses
Karina Tukanova, United Kingdom

216 What is the Time Burden and Response Rate Associated with Written or Online Completion of Health-Related Quality of Life Questionnaires after Cancer Treatment?
Fredrik Klevebro, Sweden

217 Safety of Esophageal Dilation in patients with Eosinophilic Esophagitis in a single center Cohort
Weidan Zhao, United States

219 The Role of PET-CT in the Evaluation of Lymph Node Involvement in Esophageal and Gastroesophageal Junction Carcinoma - A 5-year Single Center Experience
Eustratia Mpaili, Greece

220 Development of a new psychological tool to improve patient abilities to deal with esophagectomy: preliminary results
Alessandro Fabbian, Italy

221 The Role of Subcarinal Lymph Node Dissection in Esophagectomy - A 5-year Single Center Experience
Eustratia Mpaili, Greece

222 Evaluation of Single- Nucleotide Polymorphisms in Esophageal Carcinoma patients in Greece- Preliminary Results of a case control study
Eustratia Mpaili, Greece

223 Bilateral recurrent laryngeal nerve lymphadenectomy during thoracoscopic esophagectomy in prone position
Raquel Jiménez-Rosellón, Spain
Venue – Dates
Megaron Athens International Conference Centre (Vas. Sofias & Kokkali Str., Athens, Tel. +30 210 7282000)

Congress & Exhibition
Opening Hours
- Wednesday 20 November 2019
  08:00-19:30
- Thursday 21 November 2019
  08:00-19:00
- Friday 22 November 2019
  08:00-17:30

Coffee Breaks & Snack Lunch
Coffee breaks and snack lunch are included in the Registration fees

Language
ENGLISH is the official Congress language

ESDE Business Meeting
ESDE Business Meeting will take place on
- Thursday, 21 November 2019
  17:45 - 18:45
  Hall B (MC 2)

Registration

<table>
<thead>
<tr>
<th>Registration type</th>
<th>Early Bird Registration till 30/6/2019</th>
<th>Late Registration after 30/6/2019 and On site</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESDE Members</td>
<td>350 €</td>
<td>400 €</td>
</tr>
<tr>
<td>Non-ESDE Members</td>
<td>450 €</td>
<td>500 €</td>
</tr>
<tr>
<td>Residents, Trainees</td>
<td>200 €</td>
<td>230 €</td>
</tr>
<tr>
<td>Students</td>
<td>Free of charge</td>
<td>Free of charge</td>
</tr>
<tr>
<td>Pre-Congress Courses</td>
<td>150 €</td>
<td>200 €</td>
</tr>
<tr>
<td>Congress Dinner on 21.11.2019</td>
<td>100 €</td>
<td>100 €</td>
</tr>
</tbody>
</table>

Registration fees include:
- Access to the scientific sessions & industry exhibition
- Congress material (1 final programme, 1 congress name badge, 1 congress bag)
- Certificate of attendance
- Coffee breaks, Light lunch
- Opening Ceremony & Welcome Reception on Wednesday November 20th

VAT 24% will apply in case of invoicing
CME credits
The Congress has been granted 14 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®).

Certificates of Attendance
Certificate of attendance of the ESDE 2019 Meeting will be available online the last day of the Congress. A personalized certificate will be sent by e-mail to each registered participant against his/her badge on Friday November 22nd.

Internet Corner
Participants will have the opportunity to access e-mail at the internet corner located at the exhibition area, operating during congress hours.

Congress Dinner
This year’s ESDE Congress Dinner will be a unique experience!
On Thursday November 21st, at 19:00 the Acropolis Museum opens exclusively for ESDE Delegates.

- Dinner in the Acropolis Museum
  Restaurant with panoramic views of the Acropolis.
- Private tour by accredited English speaking guides to the famous exhibition of the Acropolis Museum.
A fantastic opportunity to mix with other delegates, speakers and industry representatives under the spell of Acropolis in one of the best Museums in the world.
Ticket’s cost: 100 Euro per person
To attend the dinner please contact the Congress Secretariat by Thursday, November 21st at 11 am.

Accommodation

<table>
<thead>
<tr>
<th>Hotel name</th>
<th>Hotel category</th>
<th>Distance from the Venue</th>
<th>Single</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crowne Plaza Hotel</td>
<td>5*</td>
<td>500 m.</td>
<td>150 €</td>
</tr>
<tr>
<td>Golden Age Hotel</td>
<td>4*</td>
<td>800 m.</td>
<td>130 €</td>
</tr>
<tr>
<td>Alexandros Hotel</td>
<td>3*</td>
<td>500 m.</td>
<td>100 €</td>
</tr>
</tbody>
</table>

Above prices are subject additionally to Municipality Tax only (to be paid at the hotel reception)

Programme changes
Should last minute changes due to functional, private or organizational needs to be necessary, all changes will be announced by the Congress Secretariat. The event organizer accepts no liability for any additional costs caused by a change of the programme.
Scientific presentations and PC reception

The Congress Halls offer full audio-visual equipment. A PC Reception desk will be available at the Congress area. All presentations should be clearly labeled with the author’s name and session’s title. All speakers are kindly requested to deliver their presentations at least 2 hours prior to the session they participate.

Badges and Security

It is essential that all participants wear their personal badge at all times in the Congress area, as it is the official entrance pass to scientific sessions. The badge is mandatory also for the Welcome Cocktail to be held on Wednesday November 20th following the Opening Ceremony of the congress.

- **BLUE COLOR** badge Participant
- **RED COLOR** badge Faculty Member
- **ORANGE COLOR** badge ESDE Executive Board Member/OC Members
- **GREEN COLOR** badge Exhibitor

Oral Presentations

Oral Presentations will be presented according to the Final Programme. All presenters should contact the PC reception desk at least 2 hours prior to their session, to ensure the technicians load their presentation. Speakers of the morning sessions should deliver their material the day before their presentation. Each oral presentation should last 8 minutes.

Posters

Posters will be presented on poster panels according to the numbers given in the Final Programme at the designated area of the congress venue.

Disclaimer

Neither the organizer nor ERA Ltd shall be liable for accidents, body injuries, theft as well as for additional costs due to the change of event date, location, programme, or similar Liability for additional costs due to delays, changes or cancellations of flights, trains or other means of transport as well as due to strike action, illness, weather or environmental disasters is also excluded. It is the responsibility of each participant to arrange appropriate theft-, accident-, health as well as travel cancellation insurance. Participants take part at their own responsibility and risk.

Congress Secretariat and Travel Agency

**ERA Ltd**

CONGRESSES • EVENTS
BUSINESS TRAVEL
INCENTIVES • TOURISM
17, Askliipiou Str.,
106 80 Athens – Greece
Tel.: +30 210 3634 944
Fax: +30 210 3631 690
E-mail: info@era.gr
Web Site: www.era.gr
Scientific Meetings

08:00 - 16:30
Examination in UEMS
Upper GI surgery

TUESDAY, NOVEMBER 19, 2019
SOCRATES B, Crowne Plaza hotel

07:30 - 08:30
ESODATA Group

THURSDAY, NOVEMBER 21, 2019
MC 3.4

13:00 - 14:00
UGIRA Robotic Group

THURSDAY, NOVEMBER 21, 2019
MC 3.3

13:00 - 14:00
TENTACLE Study Group

FRIDAY, NOVEMBER 22, 2019
MC 3.2

13:00 - 14:00
CARDIA Trial Meeting

FRIDAY, NOVEMBER 22, 2019
MC 3.4
MAVROGENIS
Established in 1990, Anastasios Mavrogenis S.A. is the authorized distributor of world’s leading companies of medical devices and surgical instruments such as Coloplast, Medtronic, Bausch & Lomb, Abbott, Genadyne and Amoena in Greece. In the heart of our values lies our passion to make the difference in people’s quality of life. By being closely to the people who use our products – patients as well as specialists and nurses who care for them – we get a better understanding of their needs and challenges and enable us to support them by offering innovative high quality products and services.
Email: info@mavrogenis.com, Tel:+30210202032

MEDTRONIC
Making healthcare better is our priority, and we believe medical technology can play an even greater role in improving people’s lives. With challenges facing families and healthcare systems – such as rising costs, aging populations, and the burden of chronic disease – we are using the power of technology to take healthcare Further, Together. Innovation and collaboration are central to who we are. Since the late 1940s, we have been working with others to alleviate pain, restore health, and extend life. Today, we are a medical technology leader, employing more than 84,000 people worldwide, and offering therapies and solutions that enable greater efficiency, access, and value – for healthcare systems, providers, and the people they serve. Learn more at https://www.medtronic.com/uk-en/index.html
SILVER SPONSOR

HOSPITAL LINE

Hospital Line Group, established in Athens, Greece, in 1993. Since year 2000, H.L has expanded its activities to the rest of the Balkan countries and today we are already present in Romania, Bulgaria, Serbia, and North Macedonia as well as in Cyprus. Our presence in the above-mentioned countries is made through our own subsidiary companies. Our company’s policy is to focus and concentrate on specialty products, with priority to products involving innovation, quality and reliability. The success of H.L is the collective dedication of our staff, which consists of 60 employees.

Our activity is oriented in two fields, Pharmaceuticals and Medical Devices, and we are one of the few companies in Greece that are active in both businesses. The main market fields of Medical Devices market, in which H.L keeps very important position, are:

- Cardiac Surgery
- General and Laparoscopic Surgery
- Vascular Surgery
- Interventional Radiology and Cardiology
- Anesthesia
- Intensive care
- Nephrology

Today our main partners in medical devices field are well-known European and American companies, such as:

- Cryolife
- LeMaitre
- Boston Scientific
- Microvention
- Merit Medical
- Endologix
- MidRay -Optcla
- Qualimed
- Angiodynamics
- COUSIN Biotech
- DOMAIN Surgical
- IGEA
- Panther Healthcare, China
- Sahajanand Medical Tech
- Bain Medical Equipment
- Bowa
Innovative Medical Devices

Hospital Line
K. Παλαμά 36, 14343, Ν. Χαλκηδόνα.
T 210 2502000, F 210 2520742,
E info@hospital-line.gr

www.hospital-line.gr
Designed to enable functional tissue remodeling for a strong repair.1

PHASIX™ ST Mesh combines two market-leading technologies into one product: monofilament resorbable PHASIX™ Mesh and a proven hydrogel barrier based on Sepra® technology. While the monofilament mesh supports functional healing and a strong repair, the hydrogel barrier minimizes tissue attachment to the visceral side of the mesh for intraabdominal placement.1

At implant

Longitudinal stripes2
- Orientation aid
- Increased visibility during placement

12 weeks post-implant

Intraabdominal placement in a porcine model.1

PHASIX™ ST Mesh
- Provides a strong, long-term repair without permanent material, as demonstrated in preclinical data3,4
- Handles, sutures, and fixates like a synthetic mesh
- Low-profile design facilitates trocar deployment during laparoscopic placement
- Primary hernia defect closure is recommended prior to placement of the mesh

Proven Barrier Using Sepra® Technology
- Used clinically since 2007
- Extensively studied barrier—more than 10 published studies2
- Hydrogel barrier resorbs within 30 days, providing visceral protection during the critical healing period1

1Preclinical data on file; results may not correlate to clinical performance in humans.
2Data on file.
3Based on PHASIX™ Mesh.
Exhibition Floor plan

HALL A (SKALKOTAS)
Conference Hall

HALL B (MC 2)
Conference Hall

HALL C (MC 3)

To Alexandra Trianti Hall

To Banquet

To HALL A (SKALKOTAS)

Coffee Break

17

11 7 6 5
YOUR HANDS & OUR TECHNOLOGY. THEY'RE MADE FOR EACH OTHER.

Tri-Staple™ 2.0 Reloads
Designed to address specific procedural challenges whilst offering real-time feedback to help guide clinical decision making.

An. Mavrogenis S.A. - Medtronic Authorized Distributor Greece
1a Gionas st. P.C.: 14451 Metamorfosi, Athens | T: +30 210 20 20 232
Acknowledgments

The Organizing Committee of ESDE 2019 gratefully acknowledges the contribution of the following sponsors:

**PLATINUM SPONSORS**

![Mavrogenis](image1)

![Medtronic](image2)

**SILVER SPONSORS**

![Hospital Line](image3)

![Ethicon](image4)

**SPONSORS**

![BD](image5)

![Bard](image6)

![Boston Scientific](image7)

![Endosim](image8)

![Proton](image9)

![Olympus](image10)

![Storz](image11)
You can install the Congress Application on your mobile phone, following the simple steps below:

• Scan the QR code above for Android or iOS
• Download from the Google Play Store or the Apple App Store the application **Events App by EventsAir**
• The first time you run the application you will be asked to input the event code. Write the word **esde2019**
• In order to personalize the app, you will need to insert your e-mail address and your personal 4-digit password, as it has been sent to your e-mail. You will have been sent the 4-digit password, as long as the Congress Secretariat has your e-mail address.

Using the app, besides having immediate access to general and useful information, you will also be able to:

• See the final program of the congress and schedule your own agenda.
• Keep notes of the sessions you are attending and easily send these to your e-mail
• Exchange your contact information with the rest of the participants of the congress
• Have the QR Code that gives you access to the congress directly saved in the app

**For Android**

![QR Code for Android]

**For iOS**

![QR Code for iOS]
Medium GastroScope for the Most Demanding Tasks

Routine working channel in the smallest package available
CONSISTENT, RELIABLE, TRUSTED

The LigaSure™ Maryland Jaw Thoracic Device
A reliable vessel sealer that specializes in thoracic surgery

Signia™ Stapling System
Automatically adapts to tissue as it fires to optimise Tri-Staple™ technology for the most consistent staple lines.

© 2018 Medtronic. All rights reserved.
18-emea-signia-ligasure-flyer-2629973
medtronic.com/covidien/en-gb/index.html

An. Mavrogenis S.A. - Medtronic Authorized Distributor Greece
1a Gionas st. P.C.: 14451 Metamorfosi, Athens | T: +30 210 20 20 232